Signal Genetics, Inc. (NASDAQ:MGEN) is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on MGEN’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that MGEN International could be a solid choice for investors.
Current Quarter Estimates for MGEN
In the past 30 days, one estimate has gone higher for Signal Genetics while none has gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 35 cents a share 30 days ago, to a loss of 29 cents a share today, a move of 17.1%.
Current Year Estimates for MGEN
Meanwhile, Signal Genetics‘s current year figures are also looking quite promising, with two estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.51 per share 30 days ago to a loss of $1.40 per share today, a move of 7.3%.
Signal Genetics, Inc. Price and EPS Surprise
Bottom Line
The stock has also started to move higher lately, adding 19.5% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Signal Genetics, Inc. (MGEN): Free Stock Analysis Report
Original post